Entries by nacnkcell

ONK Therapeutics Brings in US Financial Experience with the Appointment of Dr. Allan Reine as Independent Non-Executive Director

Allan Reine joins the Board as independent Non-Executive Director Brings significant experience as CFO of NASDAQ-listed biotechs, where he helped raise over $700 million Over 20 years in the biotechnology industry with relevant experiences as a biotech CFO, portfolio management, sell-side analyst and investment banking Galway, Ireland and San Diego, USA, 23 March 2022 – […]

Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer

Collaboration combines Intellia’s genome editing platform with ONK’s optimized natural killer (NK) cell therapy platform Intellia grants ONK non-exclusive rights to its ex vivo genome editing and LNP delivery technologies and exclusive rights to certain guide RNAs for up to five allogeneic CRISPR-edited NK cell therapies ONK is responsible for the research, clinical development and […]